A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
← catalyst calendarSponsored by Angiodynamics, Inc. (industry) · ANGO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
528estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-23 | actual | When the study began enrolling |
| Primary completion | Apr 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2019-04-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Stage III Pancreatic Cancer
Interventions
- Drug: Modified FOLFIRINOX Regimen
- Device: NanoKnife System
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured Time (in months) from randomization to the date of death for any reason, assessed through at least 24 months.
Publications
- PMID 34233640 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ANGO's whole pipeline · Catalyst calendar · Every registered study · What changed